Loading...
XCSE
CHEMM
Market cap1.50bUSD
Oct 20, Last price  
576.00DKK
1D
1.59%
1Q
42.22%
Jan 2017
1,564.74%
IPO
2,996.77%
Name

Chemometec A/S

Chart & performance

D1W1MN
XCSE:CHEMM chart
P/E
49.36
P/S
19.50
EPS
11.67
Vol. 1Y
71.76%
Shs. 5Y
-0.01%
Rev. 5Y
12.70%
Div Yld LY
1.22%
Div Yld TTM
—
Revenues
511m
+3.12%
22,310,00044,823,00032,052,00032,608,00037,231,00039,201,00041,396,00045,229,00061,239,00085,232,00090,329,000112,687,000175,513,000214,101,000281,127,000428,391,000444,401,000407,870,000495,572,000511,057,000
Net income
202m
+8.28%
843,00013,230,0004,598,000-3,687,000108,000-9,868,000346,0001,150,0007,948,00010,483,0007,486,00018,215,00041,845,00059,163,00088,354,000159,469,000178,667,000136,284,000186,405,000201,836,000
CFO
210m
+1.40%
-812,0001,341,00015,333,0006,709,0007,794,0008,865,0007,819,0005,667,00013,394,00017,200,0009,757,00025,436,00058,310,00072,016,000107,901,000176,860,000154,146,000129,002,000207,449,000210,356,000
Dividend
Oct 10, 20257 DKK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Allerød, Denmark, and established in 1997, ChemoMetec A/S focuses on the design, production, and worldwide distribution of analytical instruments for cell enumeration and analysis. Their sophisticated solutions are utilized across diverse fields, including cell-based therapeutics, oncology and stem cell research, pharmaceutical development and manufacturing, along with quality assurance for animal semen and beer. The company's product offerings feature a range of NucleoCounter devices, such as the NC-3000 advanced image cytometer, the NC-250 automated cell analyzer, and the consistent NC-202 and NC-200 automated cell counters for viability assessment. Specialized counters include the NucleoCounter SP-100 for automated sperm cell analysis in animal production, the SCC-100 for measuring somatic cells in milk samples, and the YC-100 for total count and viability of yeast cells. Beyond equipment, they also supply vital consumables like cassettes and reagents, various accessories such as software and cables, and offer extensive service and validation plans.

Key people

Martin Behrens
Chief Executive Officer · since 2024
Kim Nicolajsen
Chief Financial Officer · since 2024
Martin Glensbjerg
Vice Chairman of the Board · since 2024
Niels Thestrup
Chairman of the Board · since 2021
Kristine Faerch
Independent Director · since 2020
Betina Hagerup
Independent Director · since 2021
Peter Reich
Independent Director · since 2014
IPO date
Dec 18, 2006
Employees
Domiciled in
DK
Incorporated in
DK
Headquarters & legal address
GYDEVANG 43
ALLERØD, 85 3450
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT